Table 4.

Comparison of biomarker expression between placebo and tamoxifen groups in on-treatment and posttreatment follow-up periods

Years 0–8, on treatmentYears >8, posttreatment
ParameterTamoxifenPlaceboPTamoxifenPlaceboP
N40443956
ER
 AllMedian H-score (IQR)83.0 (0–151.9)118.9 (30.7–181.2)0.043107.5 (0–182.3)162.1 (103.0–195.0)0.018
 ER+Median H-score (IQR)104 (71.2–165.0)148.5 (81.1–182.7)0.148162.8 (110.5–191.4)169.5 (134.2–196.3)0.390
 AllPositive29 (73%)37 (84%)25 (64%)48 (86%)
Negative11 (27%)7 (16%)0.19614 (36%)8 (14%)0.014
PgR
 AllMedian H-score (IQR)55.2 (0–111.3)73.4 (0.8–167.6)0.58252.9 (0–167.7)101.3 (3.5–168.4)0.272
 PgR+Median H-score (IQR)92.3 (52.3–172.8)96.5 (67.0–180.8)0.988146 (90.6–187.7)121.4 (59.6–180.0)0.291
AllPositive27 (68%)32 (73%)23 (59%)44 (79%)
Negative13 (32%)12 (27%)0.60116 (41%)12 (21%)0.039
ER/PgR
ER+/PgR+26322344
ER+/PgR3524
ER/PgR+1000
ER/PgR107148
Ki67
 AllMedian % +ve (IQR)9.9 (4.7–20.4)9.1 (3.3–18.3)0.66010.9 (5.4–47.0)10.9 (4.6–18.2)0.180
HER2
 AllPositive5 (12%)6 (14%)7 (18%)4 (7%)
Negative35 (88%)38 (86%)0.87732 (82%)52 (93%)0.105
EGFR
 AllPositive6 (15%)6 (14%)9 (23%)6 (11%)
Negative34 (85%)37 (86%)0.89230 (77%)50 (89%)0.104